Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
Abstract New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine spec...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-12-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-021-00419-z |
| _version_ | 1797642611151863808 |
|---|---|
| author | Ria Lassaunière Charlotta Polacek Gregers J. Gram Anders Frische Jeanette Linnea Tingstedt Maren Krüger Brigitte G. Dorner Anthony Cook Renita Brown Tatyana Orekov Tammy Putmon-Taylor Tracey-Ann Campbell Jack Greenhouse Laurent Pessaint Hanne Andersen Mark G. Lewis Anders Fomsgaard |
| author_facet | Ria Lassaunière Charlotta Polacek Gregers J. Gram Anders Frische Jeanette Linnea Tingstedt Maren Krüger Brigitte G. Dorner Anthony Cook Renita Brown Tatyana Orekov Tammy Putmon-Taylor Tracey-Ann Campbell Jack Greenhouse Laurent Pessaint Hanne Andersen Mark G. Lewis Anders Fomsgaard |
| author_sort | Ria Lassaunière |
| collection | DOAJ |
| description | Abstract New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted. |
| first_indexed | 2024-03-11T14:02:29Z |
| format | Article |
| id | doaj.art-eb1cc7b9d0d241ab959968f66a8f49b5 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-11T14:02:29Z |
| publishDate | 2021-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-eb1cc7b9d0d241ab959968f66a8f49b52023-11-02T04:12:20ZengNature Portfolionpj Vaccines2059-01052021-12-016111310.1038/s41541-021-00419-zPreclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2Ria Lassaunière0Charlotta Polacek1Gregers J. Gram2Anders Frische3Jeanette Linnea Tingstedt4Maren Krüger5Brigitte G. Dorner6Anthony Cook7Renita Brown8Tatyana Orekov9Tammy Putmon-Taylor10Tracey-Ann Campbell11Jack Greenhouse12Laurent Pessaint13Hanne Andersen14Mark G. Lewis15Anders Fomsgaard16Department of Virus and Microbiological Special Diagnostic, Statens Serum InstitutDepartment of Virus and Microbiological Special Diagnostic, Statens Serum InstitutDepartment of Business Support and Campus, Statens Serum InstitutDepartment of Virus and Microbiological Special Diagnostic, Statens Serum InstitutDepartment of Virus and Microbiological Special Diagnostic, Statens Serum InstitutBiological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch InstituteBiological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch InstituteBIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.BIOQUAL Inc.Department of Virus and Microbiological Special Diagnostic, Statens Serum InstitutAbstract New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.https://doi.org/10.1038/s41541-021-00419-z |
| spellingShingle | Ria Lassaunière Charlotta Polacek Gregers J. Gram Anders Frische Jeanette Linnea Tingstedt Maren Krüger Brigitte G. Dorner Anthony Cook Renita Brown Tatyana Orekov Tammy Putmon-Taylor Tracey-Ann Campbell Jack Greenhouse Laurent Pessaint Hanne Andersen Mark G. Lewis Anders Fomsgaard Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 npj Vaccines |
| title | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 |
| title_full | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 |
| title_fullStr | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 |
| title_full_unstemmed | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 |
| title_short | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 |
| title_sort | preclinical evaluation of a candidate naked plasmid dna vaccine against sars cov 2 |
| url | https://doi.org/10.1038/s41541-021-00419-z |
| work_keys_str_mv | AT rialassauniere preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT charlottapolacek preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT gregersjgram preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT andersfrische preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT jeanettelinneatingstedt preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT marenkruger preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT brigittegdorner preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT anthonycook preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT renitabrown preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT tatyanaorekov preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT tammyputmontaylor preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT traceyanncampbell preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT jackgreenhouse preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT laurentpessaint preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT hanneandersen preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT markglewis preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 AT andersfomsgaard preclinicalevaluationofacandidatenakedplasmiddnavaccineagainstsarscov2 |